https://www.sec.gov/ix?doc=/Archives/edgar/data/0001711279/000171127926000050/krys-20260721.htm

NEW YORK, July 20, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the

https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260720-1484359/1484359_tmhc-av

B of A Securities analyst Alec Stranahan maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and r

The sky is the limit for these companies.

Krystal Biotech (KRYS) witnessed a jump in share price last session on above-average trading volume.

Entertainment leader Sphere stock continues to outperform in the current market environment, setting

As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different grou

As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different grou

TD Cowen analyst Ritu Baral maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises the pri

Moderna is racing towards important clinical and regulatory catalysts. Krystal Biotech still has a l

HC Wainwright & Co. analyst Joseph Pantginis maintains Krystal Biotech (NASDAQ:KRYS) with a B

Investors need to pay close attention to KRYS stock based on the movements in the options market lat

KRYS shares climb 16% in three months as Vyjuvek revenues jump 32%, pipeline programs advance and a

Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock?

HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a

NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP

VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to

VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to

HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a

https://www.gov.uk/government/news/mhra-approves-beremagene-geperpavec-vyjuvek-for-the-treatment-of-

Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcrip

This genetic disorder treatment developer's stock hit a buy point after the biotech's first-quarter

Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow

PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) to

Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross

Krystal Biotech Inc (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.

Krystal Biotech (KRYS) reported strong Q1 earnings, beating analyst estimates and with potential for

KRYS shares jump after a Q1 beat as Vyjuvek fuels 32% revenue growth, strong uptake and global expan

Citigroup analyst Yigal Nochomovitz maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and raises

Evercore ISI Group analyst Gavin Clark-Gartner maintains Krystal Biotech (NASDAQ:KRYS) with a Out

HC Wainwright & Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:KRYS) with a

Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.83 per share which beat the analyst

Wolfe Research analyst Kalpit Patel initiates coverage on Krystal Biotech (NASDAQ:KRYS) with a Pe

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn

  During Monday's morning session, 230 companies made new 52-week highs.

Stocks that Broke 52-Week Highs Tuesday